From the perspective of the healthcare system, both amivantamab–lazertinib combination therapy and lazertinib monotherapy demonstrate inferior cost-effectiveness compared to osimertinib as first-line treatments for advanced NSCLC patients harboring EGFR exon 20 insertion mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.